Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Depreciation & Amortization (CF) (2016 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed Depreciation & Amortization (CF) for 11 consecutive years, with $10552.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Depreciation & Amortization (CF) rose 403.68% year-over-year to $10552.0, compared with a TTM value of $20205.0 through Sep 2025, down 4.82%, and an annual FY2024 reading of $19205.0, down 62.92% over the prior year.
  • Depreciation & Amortization (CF) was $10552.0 for Q3 2025 at Kiora Pharmaceuticals, up from $3423.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $22477.0 in Q2 2023 and bottomed at $318.0 in Q1 2025.
  • Average Depreciation & Amortization (CF) over 5 years is $8835.3, with a median of $10315.0 recorded in 2023.
  • Peak annual rise in Depreciation & Amortization (CF) hit 403.68% in 2025, while the deepest fall reached 93.47% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $11036.0 in 2021, then fell by 2.38% to $10773.0 in 2022, then decreased by 26.34% to $7935.0 in 2023, then fell by 25.49% to $5912.0 in 2024, then skyrocketed by 78.48% to $10552.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for KPRX at $10552.0 in Q3 2025, $3423.0 in Q2 2025, and $318.0 in Q1 2025.